The Scientific Program Committee of the American Association for the Study of Liver Diseases (AASLD) have selected Genoscience Pharma’s abstract for oral presentation at The Liver Meeting® 2023 in Boston, MA, USA.
During the session “Insights into Basic Mechanisms of Hepatocarcinogenesis” scheduled from 11 am CET at Republic Ballroom (Sheraton), Sheraton Boston Hotel, Philippe HALFON presented at 11:45 am on Monday, November 13, 2023:
“EZURPIMTROSTAT AUTOPHAGY BLOCKER, A PALMITOYL-PROTEIN THIOESTERASE 1 (PPT1) INHIBITOR, AND ATEZOLIZUMAB/BEVACIZUMAB TRIPLE COMBINATION REGIMEN ENHANCES ANTITUMOR EFFICACY IN HEPATOCELLULAR CARCINOMA”
